Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LB-LR1109 + atezolizumab
- Development stage
- Unknown
- Lead developer
- LG Chem
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
LB-LR1109 + atezolizumab is an investigational combination therapy being developed by LG Chem and its subsidiary AVEO Oncology for the treatment of advanced solid tumors, specifically non-small cell lung cancer (NSCLC). LB-LR1109 is a first-in-class monoclonal antibody targeting Leukocyte Immunoglobulin Like Receptor B-1 (LILRB1), an immune checkpoint protein that cancer cells use to inhibit the activity of T cells, natural killer (NK) cells, and macrophages. Atezolizumab is a well-established anti-PD-L1 monoclonal antibody. By combining these two agents, the therapy aims to overcome multiple mechanisms of immune evasion, potentially providing a more robust anti-cancer response than monotherapy. The combination is currently being evaluated in a Phase 1a/1b clinical trial (NCT06332755) focusing on safety, tolerability, and preliminary efficacy in patients with advanced or metastatic NSCLC.
- Other names
- LB-LR1109 plus atezolizumabLB-LR-1109 plus atezolizumabLB-LR 1109 plus atezolizumab
02
Targets
LILRB1 (Leukocyte immunoglobulin-like receptor subfamily B member 1)CD274 (Programmed cell death protein 1 ligand 1)
Beyond the preview
Go deeper on LB-LR1109 + atezolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LB-LR1109 + atezolizumab.